한글목차

거담제의 동향 및 예측

세계의 거담제 시장은 2024년부터 2030년까지 CAGR 4.2%로 전망되며, 2030년까지 추정 211억 달러에 달할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 목의 건조로 이어지는 헛기침의 발생 건수 증가, 천식 및 만성 폐색성 폐 질환(COPD)과 같은 호흡기 질환 발생률의 상승, 또한 약물 제제 및 전달 방법 개발과 진보에 의한 거담제 성능의 향상입니다. 세계 거담제 시장의 미래는 병원 약국, 소매점, 약국, 온라인 약국의 각 시장에서의 기회에 의해 유망시되고 있습니다.

부문별 거담제

본 조사에서는 세계의 거담제 시장을 약제 유형별, 제형별, 제품 유형별, 유통 채널별, 지역별로 예측했습니다.

거담제 시장 인사이트

Lucintel의 예측에서 분비 촉진제는 일부 호흡기 질환의 관리에 유익하기 때문에 예측 기간 동안 더 큰 부문이 계속 될 것으로 예측했습니다.

이 시장에서 소매점은 가장 큰 부문으로 계속될 것입니다.

북미는 연구개발 활동이 활발해지고 있으며, 정부의 정책과 승인도 진행되고 있기 때문에 예측기간 중에도 최대지역으로 유지될 것입니다.

FAQ

Q1. 시장 규모는 :

A1. 세계의 거담제 시장은 2030년까지 추정 211억 달러에 이를 것으로 예상됩니다.

Q2. 시장 성장 예측은 :

A2. 세계의 거담제 시장은 2024년부터 2030년까지 CAGR 4.2%로 성장할 전망입니다.

Q3. 시장 성장에 영향을 미치는 주요 촉진요인은 :

A3. 이 시장의 주요 촉진요인은 목의 건조로 이어지는 기침의 발생 건수 증가, 천식 및 만성 폐색성 폐질환(COPD)과 같은 호흡기 질환의 발생률의 상승, 또한 약물제제 및 전달 방법의 개발이나 진보에 의한 거담제 성능의 향상입니다.

Q4. 시장의 주요 부문은 :

A4. 세계 거담제 시장의 미래는 병원 약국, 소매점, 약국, 온라인 약국의 각 시장에서의 기회에 의해 유망할 것으로 보입니다.

Q5. 시장의 주요 기업은 :

A5. 주요 거담제 기업은 다음과 같습니다.

• Abbott Laboratories
• Acella Pharmaceuticals
• AstraZeneca
• Cipla Limited
• Dabur
• Glenmark Pharmaceuticals
• Johnson and Johnson
• Merck
• Novartis International
• Pfizer

Q6. 향후 가장 큰 시장 부문은 :

A6. Lucintel은 분비 촉진제는 몇몇 호흡기 질환의 관리에 유익하기 때문에 예측 기간에 걸쳐 더 큰 부문을 유지할 것으로 예측됩니다.

Q7. 시장에서 향후 5년간 최대가 될 것으로 예상되는 지역은 :

A7. 북미는 연구개발 활동이 활발해지고 있으며, 정부의 정책과 승인도 진행되고 있기 때문에 예측기간 동안에도 최대지역으로 지속될 것으로 보입니다.

Q8. 보고서 사용자 정의는 가능한가?

A8. 그렇습니다, Lucintel는 추가 비용 없이 10% 주문을 받아서 만듭니다.

목차

제1장 주요 요약

제2장 세계의 거담제 시장 : 시장 역학

• 서문, 배경 및 분류
• 공급망
• 업계의 촉진요인 및 과제

제3장 시장 동향 및 예측 분석(2018-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 거담제 시장 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 거담제 시장 : 약제 유형별
  • 분비 촉진제
  • 점액 용해제
• 세계의 거담제 시장 : 제형별
  • 경구 고형제
  • 경구액제
  • 흡입제
• 세계의 거담제 시장 : 제품 유형별
  • 매장 약(OTC)
  • 처방 약
• 세계의 거담제 시장 : 유통 채널별
  • 병원 약국
  • 소매점
  • 약국
  • 온라인 약국
  • 기타

제4장 시장 동향 및 예측 분석(2018-2023년) : 지역별

• 지역별 세계의 거담제 시장
• 북미의 거담제 시장
• 유럽의 거담제 시장
• 아시아태평양 거담제 시장
• 기타 지역의 거담제 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회 및 전략 분석

• 성장 기회 분석
  • 약제 유형별 세계 거담제 시장의 성장 기회
  • 제형별 세계 거담제 시장의 성장 기회
  • 제품 유형별 세계 거담제 시장의 성장 기회
  • 유통 채널별 세계 거담제 시장의 성장 기회
  • 지역별 세계 거담제 시장의 성장 기회
• 세계 거담제 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계 거담제 시장의 생산능력 확대
  • 세계 거담제 시장의 합병, 인수 및 합작 사업
  • 인증 및 라이선싱

제7장 주요 기업의 기업 프로파일

• Abbott Laboratories
• Acella Pharmaceuticals
• AstraZeneca
• Cipla Limited
• Dabur
• Glenmark Pharmaceuticals
• Johnson and Johnson
• Merck
• Novartis International
• Pfizer

영문목차

Expectorant Drug Trends and Forecast

The future of the global expectorant drug market looks promising with opportunities in the hospital pharmacy, retail store, drug store, and online pharmacy markets. The global expectorant drug market is expected to reach an estimated $21.1 billion by 2030 with a CAGR of 4.2% from 2024 to 2030. The major drivers for this market are growing number of incidences of dry cough that lead to dry throats, rising rates of respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), as well as, improvements in the performance of expectorant drugs owing to developments and advances in drug formulation and delivery methods.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Expectorant Drug by Segment

The study includes a forecast for the global expectorant drug by drug type, dosage form, product type, distribution channel, and region.

Expectorant Drug Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

• Secretion Enhancer
• Mucolytics

Expectorant Drug Market by Dosage Form [Shipment Analysis by Value from 2018 to 2030]:

• Oral Solid
• Oral Liquid
• Inhalant

Expectorant Drug Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

• Over-The-Counter
• Prescription Drug

Expectorant Drug Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacies
• Retail Store
• Drug Store
• Online Pharmacies
• Others

Expectorant Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Expectorant Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies expectorant drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the expectorant drug companies profiled in this report include-

• Abbott Laboratories
• Acella Pharmaceuticals
• AstraZeneca
• Cipla Limited
• Dabur
• Glenmark Pharmaceuticals
• Johnson and Johnson
• Merck
• Novartis International
• Pfizer

Expectorant Drug Market Insights

Lucintel forecasts that secretion enhancer will remain larger segment over the forecast period due to they are beneficial in the management of several respiratory conditions.

Within this market, retail store will remain the largest segment.

North America will remain the largest region over the forecast period due to growing number of research and development activities, along with government policies and approvals in the region.

Features of the Global Expectorant Drug Market

Market Size Estimates: Expectorant drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Expectorant drug market size by drug type, dosage form, product type, distribution channel, and region in terms of value ($B).

Regional Analysis: Expectorant drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug type, dosage form, product type, distribution channel, and regions for the expectorant drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the expectorant drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the expectorant drug market size?

Answer: The global expectorant drug market is expected to reach an estimated $21.1 billion by 2030.

Q2. What is the growth forecast for expectorant drug market?

Answer: The global expectorant drug market is expected to grow with a CAGR of 4.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the expectorant drug market?

Answer: The major drivers for this market are growing number of incidences of dry cough that lead to dry throats, rising rates of respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), as well as, improvements in the performance of expectorant drugs owing to developments and advances in drug formulation and delivery methods.

Q4. What are the major segments for expectorant drug market?

Answer: The future of the global expectorant drug market looks promising with opportunities in the hospital pharmacy, retail store, drug store, and online pharmacy markets.

Q5. Who are the key expectorant drug market companies?

Answer: Some of the key expectorant drug companies are as follows:

• Abbott Laboratories
• Acella Pharmaceuticals
• AstraZeneca
• Cipla Limited
• Dabur
• Glenmark Pharmaceuticals
• Johnson and Johnson
• Merck
• Novartis International
• Pfizer

Q6. Which expectorant drug market segment will be the largest in future?

Answer: Lucintel forecasts that secretion enhancer will remain larger segment over the forecast period due to they are beneficial in the management of several respiratory conditions.

Q7. In expectorant drug market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing number of research and development activities, along with government policies and approvals in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the expectorant drug market by drug type (secretion enhancer and mucolytics), dosage form (oral solid, oral liquid, and inhalant), product type (over-the-counter and prescription drug), distribution channel (hospital pharmacies, retail store, drug store, online pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Expectorant Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Expectorant Drug Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Expectorant Drug Market by Drug Type
  • 3.3.1: Secretion Enhancer
  • 3.3.2: Mucolytics
• 3.4: Global Expectorant Drug Market by Dosage Form
  • 3.4.1: Oral Solid
  • 3.4.2: Oral Liquid
  • 3.4.3: Inhalant
• 3.5: Global Expectorant Drug Market by Product Type
  • 3.5.1: Over-The-Counter
  • 3.5.2: Prescription Drug
• 3.6: Global Expectorant Drug Market by Distribution Channel
  • 3.6.1: Hospital Pharmacies
  • 3.6.2: Retail Store
  • 3.6.3: Drug Store
  • 3.6.4: Online Pharmacies
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Expectorant Drug Market by Region
• 4.2: North American Expectorant Drug Market
  • 4.2.1: North American Expectorant Drug Market by Drug Type: Secretion Enhancer and Mucolytics
  • 4.2.2: North American Expectorant Drug Market by Distribution Channel: Hospital Pharmacies, Retail Store, Drug Store, Online Pharmacies, and Others
• 4.3: European Expectorant Drug Market
  • 4.3.1: European Expectorant Drug Market by Drug Type: Secretion Enhancer and Mucolytics
  • 4.3.2: European Expectorant Drug Market by Distribution Channel: Hospital Pharmacies, Retail Store, Drug Store, Online Pharmacies, and Others
• 4.4: APAC Expectorant Drug Market
  • 4.4.1: APAC Expectorant Drug Market by Drug Type: Secretion Enhancer and Mucolytics
  • 4.4.2: APAC Expectorant Drug Market by Distribution Channel: Hospital Pharmacies, Retail Store, Drug Store, Online Pharmacies, and Others
• 4.5: ROW Expectorant Drug Market
  • 4.5.1: ROW Expectorant Drug Market by Drug Type: Secretion Enhancer and Mucolytics
  • 4.5.2: ROW Expectorant Drug Market by Distribution Channel: Hospital Pharmacies, Retail Store, Drug Store, Online Pharmacies, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Expectorant Drug Market by Drug Type
  • 6.1.2: Growth Opportunities for the Global Expectorant Drug Market by Dosage Form
  • 6.1.3: Growth Opportunities for the Global Expectorant Drug Market by Product Type
  • 6.1.4: Growth Opportunities for the Global Expectorant Drug Market by Distribution Channel
  • 6.1.5: Growth Opportunities for the Global Expectorant Drug Market by Region
• 6.2: Emerging Trends in the Global Expectorant Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Expectorant Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Expectorant Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abbott Laboratories
• 7.2: Acella Pharmaceuticals
• 7.3: AstraZeneca
• 7.4: Cipla Limited
• 7.5: Dabur
• 7.6: Glenmark Pharmaceuticals
• 7.7: Johnson and Johnson
• 7.8: Merck
• 7.9: Novartis International
• 7.10: Pfizer